Apop Biosciences

What Apop Biosciences does

Apop Biosciences Pty Ltd is an Australian biotechnology company headquartered in Melbourne (ABN 37 615 441 113), founded in 2016, that develops the proprietary CalRexin™ platform — a calcitonin receptor monoclonal antibody technology targeting a novel extracellular marker of programmed cell death (PCD), enabling detection of apoptosis and autophagy in live stressed cells. The IP base is protected by patents and registered trademarks in Australia, the European Union, the United Kingdom, and the United States, and is positioned in company materials as a first-in-class technology with no direct market competitors. CalRexin™-based antibody:fluorophore conjugates also have downstream potential as antibody-drug conjugates and immunotoxins targeting solid tumours.

The commercial portfolio includes fluorophore-conjugated imaging reagents — CalRexin®:488, :568, :647 and :680 for apoptosis detection via flow cytometry and microscopy, and the 2024-launched CalRexin™:pHrodo™ Red for real-time, pH-sensitive autophagy imaging on high-throughput/high-content platforms. All products are sold Research Use Only (RUO). Apop distributes globally through four regional channel partners — Chameleon Science (AU/NZ), American Research Products Inc. (USA), Biozol Diagnostica (DACH), and Cedarlane/TCP Analytical Group (Canada) — supplemented by direct website sales, with a free evaluation-sample programme running through March 2026 and a 20% discount available through April 2026.

The business model combines one-time RUO reagent sales, a 2024 worldwide non-exclusive out-license agreement with a U.S.-based company covering Apop's monoclonal antibody technology, and longer-term royalty/development economics from CalRexin™-based therapeutics (ADC/immunotoxin for glioblastoma multiforme, in collaboration with two Australian and one German university) and diagnostic agents (PET imaging of PCD, theranostics). Leadership comprises CEO Elpis Barons and CSO A/Prof. Peter Wookey, against a disclosed headcount of 1–10 employees.

Name

Apop Biosciences

Legal name

Apop Biosciences Pty Ltd

Website

https://apopbiosciences.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Apop Biosciences is an Australian biotech developing the proprietary CalRexin™ monoclonal antibody platform for first-in-class imaging reagents that detect apoptosis and autophagy, selling RUO kits to academic researchers, biopharma, and CROs via global distributors.

Ownership category

akta.pro rank

Product category

Cell Biology Research Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAGAIAI

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLAAAIAA

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAGADAH

Cell-Based & Potency Assays (Bioassays)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

SECONDARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

• Cell stress imaging reagents
• Programmed cell death detection
• Autophagy imaging tools
• Apoptosis detection reagents
• Monoclonal antibody technology

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Research Reagent Sales: Apop generates revenue through the sale of CalRexin™ imaging reagents including CalRexin™:488, 568, 647, 680 conjugates for apoptosis detection and CalRexin™:pHrodo™ Red for autophagy detection. Products are sold directly and through distributor networks globally. Products are for Research Use Only (RUO).
2. Out-licensing Agreement: Apop has entered into a worldwide out-license agreement with a U.S.-based company for its monoclonal antibody technology. The agreement grants non-exclusive global rights to the licensee to develop, manufacture, and commercialize products incorporating Apop's patented technology.
3. Therapeutic Development: Apop is developing CalRexin™ into therapeutic delivery vehicles (antibody-toxin and antibody-drug conjugates) for treatment of refractory tumors, particularly glioblastoma multiforme, in partnership with Australian and German universities.
4. Diagnostic/Theranostic Development: Apop is developing novel CalRexin™ conjugates as diagnostic tools for real-time imaging of programmed cell death in patients, including PET scanning applications.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Apop Biosciences develops and sells the CalRexin™ product line—proprietary calcitonin receptor monoclonal antibody-based imaging reagents used by researchers and biotech companies to detect and monitor programmed cell death (apoptosis and autophagy) in live cells. Products include fluorophore conjugates (CalRexin™:488, :568, :647, :680) for apoptosis detection via flow cytometry and microscopy, and CalRexin™:pHrodo™ Red, a first-in-class pH-sensitive reagent for real-time autophagy imaging over 24+ hours. All products are for Research Use Only (RUO) and are sold directly and through a global distributor network.

Product overview

Apop Biosciences offers the CalRexin™ platform—a suite of proprietary imaging reagents based on calcitonin receptor monoclonal antibody technology. The platform provides first-in-class products for detecting programmed cell death (PCD) including apoptosis and autophagy. The product portfolio includes fluorophore conjugates (CalRexin®:488, :568, :647, :680) for apoptosis detection via flow cytometry and microscopy, and CalRexin™:pHrodo™ Red for autophagy imaging. All products are for Research Use Only (RUO). The company is also developing therapeutic candidates (ADC/immunotoxin for glioblastoma) and diagnostic agents (PET imaging) based on the same CalRexin™ technology.

Differentiator

Problem solved

Functional benefit

Products and services

• CalRexin™:pHrodo™ Red First-in-class pH-sensitive autophagy imaging reagent for real-time detection in live cells. Targets the activated calcitonin receptor and fluoresces brightly in low-pH environments as it moves through early endosomes to autolysosomes. Resists photobleaching, is highly stable, and supports high-throughput/content imaging of live cells for 24+ hours at multiple timepoints. For Research Use Only (RUO).
• CalRexin®:488 Fluorophore conjugate imaging reagent for apoptosis detection in live cell assays, suitable for flow cytometry and confocal microscopy. Identifies sub-populations of stressed cells including live, apoptotic, transition, and dead cells using a calcium-independent assay with no false positives. For Research Use Only (RUO).
• CalRexin®:568 Fluorophore conjugate imaging reagent for apoptosis detection, independently validated by Crux Biolabs for FACS analysis in live cell assays. Detects sub-populations of stressed cells in real time and is calcium-independent with no false positives. For Research Use Only (RUO).
• CalRexin™:647 Fluorophore conjugate imaging reagent for apoptosis detection that defines sub-populations of cells including live, apoptotic, transition, and dead cells using FACS. Designed for use in flow cytometry workflows. For Research Use Only (RUO).
• CalRexin®:680 Fluorophore conjugate imaging reagent for apoptosis detection in live cell assays. Suitable for flow cytometry and microscopy with calcium-independent staining and no false positives. For Research Use Only (RUO).

Quantifiable outcome

• Real-time autophagy monitoring over 24+ hours at multiple timepoints
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Chameleon SciencecoreChannel Partner/ Reseller/ DistributorExclusive distributor for Australia and New Zealand. Chameleon Science handles all sales and distribution of CalRexin™ imaging reagents in the AU/NZ region, providing local support and service to researchers and companies.
• American Research Products Inc.coreChannel Partner/ Reseller/ DistributorExclusive distributor for the United States of America. ARP handles sales and distribution of CalRexin™ products in the US market.
• Biozol Diagnostica Vertrieb GmbHcoreChannel Partner/ Reseller/ DistributorDistributor for Germany, Austria, and Switzerland (DACH region). Biozol handles sales and distribution of CalRexin™ products in the DACH region.
• Cedarlane (TCP Analytical Group)coreChannel Partner/ Reseller/ DistributorDistributor for Canada, part of TCP Analytical Group. Cedarlane handles sales and distribution of CalRexin™ products in the Canadian market.
• U.S.-based licensee companycoreOEM/ Whitelabel/ Licensing PartnerApop has entered into a worldwide out-license agreement granting non-exclusive global rights to this U.S.-based company to develop, manufacture, and commercialize products incorporating Apop's patented monoclonal antibody technology.
• Australian Universities (Glioblastoma Research)coreStrategic or Co-development PartnerApop is collaborating with two globally recognized Australian universities to develop CalRexin™ into therapeutic delivery vehicles (ADC/antibody:immunotoxin) for treatment of glioblastoma multiforme.
• German University (Glioblastoma Research)coreStrategic or Co-development PartnerApop is collaborating with a globally recognized German university to develop CalRexin™ into therapeutic delivery vehicles for treatment of glioblastoma multiforme.
• Gordon Research ConferenceminorOthersApop presented research at Gordon Research Conference 2024, showcasing CalRexin™:pHrodo Red as a novel pH-sensitive probe for autophagy quantification on high throughput/content imaging platforms.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/apop-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apop Biosciences